These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 38643565)

  • 1. Research progress of PROTACs for neurodegenerative diseases therapy.
    Cai Z; Yang Z; Li H; Fang Y
    Bioorg Chem; 2024 Jun; 147():107386. PubMed ID: 38643565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nano-PROTACs: state of the art and perspectives.
    Zhong J; Zhao R; Wang Y; Su YX; Lan X
    Nanoscale; 2024 Feb; 16(9):4378-4391. PubMed ID: 38305466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROTACs technology for targeting non-oncoproteins: Advances and perspectives.
    Wang C; Zhang Y; Xing D; Zhang R
    Bioorg Chem; 2021 Sep; 114():105109. PubMed ID: 34175722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety.
    Zhang R; Xie S; Ran J; Li T
    J Cell Physiol; 2024 May; 239(5):e31255. PubMed ID: 38501341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier.
    Tashima T
    Antibodies (Basel); 2023 Jun; 12(3):. PubMed ID: 37489365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
    Zhu H; Wang J; Zhang Q; Pan X; Zhang J
    Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy.
    Chen X; Shen H; Shao Y; Ma Q; Niu Y; Shang Z
    Transl Androl Urol; 2021 Feb; 10(2):954-962. PubMed ID: 33718095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.
    Chen Y; Tandon I; Heelan W; Wang Y; Tang W; Hu Q
    Chem Soc Rev; 2022 Jul; 51(13):5330-5350. PubMed ID: 35713468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Molecular Targets and Mechanisms for Neuroprotective Modulation in Neurodegenerative Disorders.
    Azari A; Goodarzi A; Jafarkhani B; Eghbali M; Karimi Z; Hosseini Balef SS; Irannejad H
    Cent Nerv Syst Agents Med Chem; 2022; 22(2):88-107. PubMed ID: 35713146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy.
    Bhole RP; Kute PR; Chikhale RV; Bonde CG; Pant A; Gurav SS
    Bioorg Chem; 2023 Oct; 139():106720. PubMed ID: 37480814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies.
    Wu Y; Zhang J; Zhu X; Zhang Y
    Cancer Lett; 2022 Sep; 544():215808. PubMed ID: 35764266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
    Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
    Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
    Setia N; Almuqdadi HTA; Abid M
    Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera.
    Tseng YL; Lu PC; Lee CC; He RY; Huang YA; Tseng YC; Cheng TR; Huang JJ; Fang JM
    J Biomed Sci; 2023 Apr; 30(1):27. PubMed ID: 37101169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteolysis targeting chimeras (PROTACs) for epigenetics research.
    Vogelmann A; Robaa D; Sippl W; Jung M
    Curr Opin Chem Biol; 2020 Aug; 57():8-16. PubMed ID: 32146413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
    Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
    Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breaking Bad Proteins-Discovery Approaches and the Road to Clinic for Degraders.
    Bouvier C; Lawrence R; Cavallo F; Xolalpa W; Jordan A; Hjerpe R; Rodriguez MS
    Cells; 2024 Mar; 13(7):. PubMed ID: 38607017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs).
    Saraswat AL; Vartak R; Hegazy R; Patel A; Patel K
    Drug Discov Today; 2023 Jan; 28(1):103387. PubMed ID: 36184017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy.
    Fang Y; Wang J; Zhao M; Zheng Q; Ren C; Wang Y; Zhang J
    J Med Chem; 2022 Sep; 65(17):11454-11477. PubMed ID: 36006861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.